MX2022007626A - Combinaciones. - Google Patents
Combinaciones.Info
- Publication number
- MX2022007626A MX2022007626A MX2022007626A MX2022007626A MX2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- disease
- treating
- compounds
- condition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952039P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065409 WO2021127044A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007626A true MX2022007626A (es) | 2022-09-23 |
Family
ID=76478095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007626A MX2022007626A (es) | 2019-12-20 | 2020-12-16 | Combinaciones. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230008362A1 (enExample) |
| EP (1) | EP4069235A4 (enExample) |
| JP (1) | JP7631348B2 (enExample) |
| KR (1) | KR20220119442A (enExample) |
| CN (1) | CN115427042A (enExample) |
| AU (1) | AU2020407070A1 (enExample) |
| BR (1) | BR112022012281A2 (enExample) |
| CA (1) | CA3165472A1 (enExample) |
| IL (1) | IL294080A (enExample) |
| MX (1) | MX2022007626A (enExample) |
| TW (1) | TW202132299A (enExample) |
| WO (1) | WO2021127044A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017517520A (ja) | 2014-05-29 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| WO2023114877A1 (en) * | 2021-12-15 | 2023-06-22 | Recurium Ip Holdings, Llc | Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents |
-
2020
- 2020-12-16 AU AU2020407070A patent/AU2020407070A1/en active Pending
- 2020-12-16 CA CA3165472A patent/CA3165472A1/en active Pending
- 2020-12-16 IL IL294080A patent/IL294080A/en unknown
- 2020-12-16 CN CN202080095235.7A patent/CN115427042A/zh active Pending
- 2020-12-16 WO PCT/US2020/065409 patent/WO2021127044A1/en not_active Ceased
- 2020-12-16 KR KR1020227025073A patent/KR20220119442A/ko not_active Ceased
- 2020-12-16 JP JP2022538220A patent/JP7631348B2/ja active Active
- 2020-12-16 US US17/757,493 patent/US20230008362A1/en not_active Abandoned
- 2020-12-16 BR BR112022012281A patent/BR112022012281A2/pt unknown
- 2020-12-16 MX MX2022007626A patent/MX2022007626A/es unknown
- 2020-12-16 EP EP20902208.6A patent/EP4069235A4/en active Pending
- 2020-12-18 TW TW109145139A patent/TW202132299A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202132299A (zh) | 2021-09-01 |
| JP2023508328A (ja) | 2023-03-02 |
| WO2021127044A1 (en) | 2021-06-24 |
| KR20220119442A (ko) | 2022-08-29 |
| US20230008362A1 (en) | 2023-01-12 |
| EP4069235A1 (en) | 2022-10-12 |
| JP7631348B2 (ja) | 2025-02-18 |
| AU2020407070A1 (en) | 2022-07-14 |
| CN115427042A (zh) | 2022-12-02 |
| BR112022012281A2 (pt) | 2022-08-30 |
| CA3165472A1 (en) | 2021-06-24 |
| EP4069235A4 (en) | 2024-01-10 |
| IL294080A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007626A (es) | Combinaciones. | |
| PT3883579T (pt) | Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| LT3986897T (lt) | Egfr inhibitorius, skirtas vėžiui gydyti | |
| MX2022007628A (es) | Combinaciones. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| MX2022007623A (es) | Combinaciones. | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| BR112022012278A2 (pt) | Combinações | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| PH12017501882A1 (en) | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| MX2022005522A (es) | Formas de sal de un receptor de componente c5a de complemento. | |
| CO2017009182A2 (es) | Cepas bacterianas productoras de histamina para tratamiento del cáncer | |
| WO2018005444A3 (en) | Methods for treating cancer |